Effect of Non-alcoholic Fatty Liver Disease on Some of Bone Biomarkers in Men

Dalal Al-Akabi; Faris S. Kata

doi:10.3889/oamjms.2021.6892

Authors

Dalal Al-Akabi Department of Medical Laboratory Techniques, Al-Kunooze University College, Basrah, Iraq https://orcid.org/0000-0003-2939-3621
Faris S. Kata Department of Biology, College of Education For Pure Sciences, University of Basrah, Basrah, Iraq

DOI:

https://doi.org/10.3889/oamjms.2021.6892

Keywords:

Non-alcoholic fatty liver disease, Osteocalcin, Sclerostin, Bone sialoprotein

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is one of the common liver diseases worldwide that is not associated with alcohol consumption; it is a group of disorders caused by fat accumulation in the liver.

AIM: The research aims to assess the levels of serum sialoprotein, sclerostin, and osteocalcin in men with NAFLD.

METHODS: The current study was conducted in Basra city, Iraq in 2020, which includes 400 men with NAFLD, age ranges between (30 and 50) years, and 400 matched health men as controls, serum levels of study parameters were measured using the ELISA method.

RESULTS: The results showed a significant decrease in the levels of serum osteocalcin but a non-significant difference in sclerostin and bone sialoprotein in men with NAFLD comparing with the control group, also age and disease severity factors did not show any significant effect on study parameters in the patient’s group.

CONCLUSION: In conclusion, men with NAFLD may be prone to some disturbances in the bone health regardless of disease progression and age in Basrah city.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Ann Rev Pathol. 2018;13:321-50. https://doi.org/10.1146/annurev-pathol-020117-043617 PMid:29414249 DOI: https://doi.org/10.1146/annurev-pathol-020117-043617

Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Ann Rev Physiol. 2016;78:181-205. https://doi.org/10.1146/annurev-physiol-021115-105331 PMid:26667070 DOI: https://doi.org/10.1146/annurev-physiol-021115-105331

Calzadilla BL, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5):774. https://doi.org/10.3390/ijms17050774 PMid:27213358 DOI: https://doi.org/10.3390/ijms17050774

Akkawi I, Zmerly H. Osteoporosis: Current concepts. Joints. 2018;6(2):122-7. https://doi.org/10.1055/s-0038-1660790 PMid:30051110 DOI: https://doi.org/10.1055/s-0038-1660790

Kumar P, Saini M, Kumar D, Bharadwaj A, Yadav PS. Estimation of endogenous levels of osteopontin, total antioxidant capacity and malondialdehyde in seminal plasma: Application for fertility assessment in buffalo (Bubalus bubalis) bulls. Reprod Domest Anim. 2017;52(2):221-6 https://doi.org/10.1111/rda.12882 PMid:27862407 DOI: https://doi.org/10.1111/rda.12882

Eshraghian A. Bone metabolism in non-alcoholic fatty liver disease: Vitamin D status and bone mineral density. Miner Endocrinol. 2017;42(2):164-72. https://doi.org/10.23736/s0391-1977.16.02587-6 PMid:27973461 DOI: https://doi.org/10.23736/S0391-1977.16.02587-6

Shateri K, Vousoghian S, Oshnoei S, Mohammadi A. Association of osteoporosis with non-alcoholic fatty liver disease in adults. J Adv Pharm Educ Res. 2019;9(2):408.

Shen Z, Cen L, Chen X, Pan J, Li Y, Chen W, et al. Increased risk of low bone mineral density in patients with non-alcoholic fatty liver disease: A cohort study. Eur J Endocrinol. 2020;182(2):157-64. https://doi.org/10.1530/eje-19-0699 PMid:31770104 DOI: https://doi.org/10.1530/EJE-19-0699

Danford CJ, Trivedi HD, Bonder A. Bone health in patients with liver diseases. J Clin Densitom. 2020;23(2):212-22. https://doi.org/10.1016/j.jocd.2019.01.004 PMid:30744928 DOI: https://doi.org/10.1016/j.jocd.2019.01.004

Filip R, Radzki RP, Bieńko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging. 2018;13:1879-91. https://doi.org/10.2147/cia.s170533 PMid:30323574 DOI: https://doi.org/10.2147/CIA.S170533

Stein EM, Cohen A, Freeby M. Severe Vitamin D deficiency among heart and liver transplant recipients. Clin Transplant. 2009;23(6):861-5. https://doi.org/10.1111/j.1399-0012.2009.00989.x PMid:19453643 DOI: https://doi.org/10.1111/j.1399-0012.2009.00989.x

Berezovska O, Yildirim G, Budell WC. Osteocalcin affects bone mineral and mechanical properties in female mice. Bone. 2019;128:115031. https://doi.org/10.1016/j.bone.2019.08.004 PMid:31401301 DOI: https://doi.org/10.1016/j.bone.2019.08.004

Aller R, Castrillon JL, de Luis DA. Relation of osteocalcin with insulin resistance and histopathological changes of nonalcoholic fatty liver disease. Ann Hepatol. 2016;10(1):50-5. https://doi.org/10.1016/s1665-2681(19)31587-x PMid:21301010 DOI: https://doi.org/10.1016/S1665-2681(19)31587-X

Hu X, Hua Y, Shi Z. Association of serum 25-hydroxy Vitamin D and osteocalcin levels with non-alcoholic fatty liver disease. Int J Clin Exp Med. 2016;9(11):22750-7.

Du J, Zhang M, Lu J. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK. Endocrine. 2016;53(3):701-9. https://doi.org/10.1007/s12020-016-0926-5 PMid:26994931 DOI: https://doi.org/10.1007/s12020-016-0926-5

Ebrahim HT, El-Behery EG. Osteocalcin: A new biomarker for nonalcoholic fatty liver disease (NAFLD) in children and adolescents. Clin Med Biochem. 2017;3:2471-663. https://doi.org/10.4172/2471-2663.1000133 DOI: https://doi.org/10.4172/2471-2663.1000133

Yang HJ, Shim SG, Ma BO, Kwak JY. Association of nonalcoholic fatty liver disease with bone mineral density and serum osteocalcin levels in Korean men. J Gastroenterol Hepatol. 2016;28(3):338-44. https://doi.org/10.1097/meg.0000000000000535 PMid:26636404 DOI: https://doi.org/10.1097/MEG.0000000000000535

Fernández-Real JM, Ortega F, Gómez-Ambrosi J, Salvador J, Frühbeck G, Ricart W. Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. Osteoporos Int. 2010;21(12):2101-7. https://doi.org/10.1007/s00198-010-1174-9 PMid:20204603 DOI: https://doi.org/10.1007/s00198-010-1174-9

Dou J, Ma X, Fang Q. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in Chinese men. Clin Exp Pharmacol Physiol. 2013;40(4):282-8. https://doi.org/10.1111/1440-1681.12063 PMid:23369196 DOI: https://doi.org/10.1111/1440-1681.12063

Xia M, Rong S, Zhu X, Yan H, Chang X, Sun X, et al. Osteocalcin and non-alcoholic fatty liver disease: Lessons from two population-based cohorts and animal models. J Bone Miner Res. 2021;36(4):712-28. https://doi.org/10.1002/jbmr.4227 PMid:33270924 DOI: https://doi.org/10.1002/jbmr.4227

Zhang M, Nie X, Yuan Y, Wang Y, Ma X, Yin J, et al. Osteocalcin alleviates nonalcoholic fatty liver disease in mice through GPRC6A. Int J Endocrinol. 2021;2021:9178616. https://doi.org/10.1155/2021/9178616 PMid:33531899 DOI: https://doi.org/10.1155/2021/9178616

Mantovani A, Sani E, Fassio A. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with Type 2 diabetes. Diabetes Metab. 2019;45(4):347-55. https://doi.org/10.1016/j.diabet.2018.10.001 PMid:30315891 DOI: https://doi.org/10.1016/j.diabet.2018.10.001

Neong SF, Billington EO, Congly SE. Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: Review of pathogenesis and management. Hepatology. 2018;69(6):2683-95. https://doi.org/10.1002/hep.30359 DOI: https://doi.org/10.1002/hep.30359

Polyzos SA, Anastasilakis AD, Kountouras J. Circulating sclerostin and dickkopf-1 levels in patients with nonalcoholic fatty liver disease. J Bone Miner Metab. 2016;34(4):447-56. https://doi.org/10.1007/s00774-015-0687-x PMid:26056025 DOI: https://doi.org/10.1007/s00774-015-0687-x

Guañabens N, Parés A. Osteoporosis in chronic liver disease. Liver Int. 2018;38(5):776-85. https://doi.org/10.1111/liv.13730 PMid:29479832 DOI: https://doi.org/10.1111/liv.13730

Yang YJ, Kim DJ. An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: Osteoporosis, sarcopenia, and osteoporotic Sarcopenia. Int J Mol Sci. 2021;22(5):2604. https://doi.org/10.3390/ijms22052604 PMid:33807573 DOI: https://doi.org/10.3390/ijms22052604

Mantovani A, Gatti D, Zoppini G. Association between nonalcoholic fatty liver disease and reduced bone mineral density in children: A meta-analysis. Hepatology. 2019;70(3):812-23. https://doi.org/10.1002/hep.30538 PMid:30706504 DOI: https://doi.org/10.1002/hep.30538

Harvey B. The Characterization of the Rat Bone Sialoprotein Knockout Phenotype. Canada: Western University; 2019.

Benz F, Bogen A, Praktiknjo M. Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis. PLoS One. 2020;15(4):e0231701. https://doi.org/10.1371/journal.pone.0231701 PMid:32302330 DOI: https://doi.org/10.1371/journal.pone.0231701

Bruha R, Vitek L, Smid V. Osteopontin-a potential biomarker of advanced liver disease. Ann Hepatol. 2020;19(4):344-52. https://doi.org/10.1016/j.aohep.2020.01.001 PMid:32005637 DOI: https://doi.org/10.1016/j.aohep.2020.01.001

Mantovani A, Dauriz M, Gatti D. Systematic review with meta-analysis: Non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. Aliment Pharmacol Ther. 2019;49(4):375-88. https://doi.org/10.1111/apt.15087 PMid:30600540 DOI: https://doi.org/10.1111/apt.15087

Mahmoud NS, Mohamed MR, Ali MA. Osteoblast-based therapy-a new approach for bone repair in osteoporosis: Pre-clinical setting. Tissue Eng Regen Med. 2020;17(3):363-73. https://doi.org/10.1007/s13770-020-00249-5 PMid:32347454 DOI: https://doi.org/10.1007/s13770-020-00249-5